October 3, 2019 11:13 AM EDTUpdated 11:45 AM

Aeovian Pharmaceuticals brings in $37 million in mTOR play

Jason Mast

Editor

San Francisco-based Aeovian Pharmaceuticals has banked $37 million in Series A financing to launch its mTORC1 inhibitor into a proof-of-concept for what the company says …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Aeovian Pharmaceuticals brings in $37 million in mTOR play

Jason Mast

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

Rare disease biopharma companies weigh in on FDA's new innovation hub

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Aeov­ian Phar­ma­ceu­ti­cals brings in $37 mil­lion in mTOR play

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Aeovian Pharmaceuticals brings in $37 million in mTOR play